Early in the coronavirus pandemic, alarming reports suggested that COVID-19 was more than just a severe respiratory disease. Clinicians quickly learned that the disease could have a dire impact on cardiovascular health and sometimes seemed to attack the heart directly.
Over the following months, hypotheses and speculation gave way to a solid understanding of the cardiovascular risks associated with a COVID-19. Viral infections are notorious for putting added pressure on the system in the form of inflammation, which in turn leads to adverse health outcomes such as cardiovascular injury or disease and strokes, but early data suggested that SARS-CoV-2 is exceptional.
It turns out that COVID-19 can involve a variety of cardiovascular health outcomes. Scientists from the CDC COVID-19 Response Team found that COVID-19 patients have a 16-fold increase in the risk of developing the inflammatory conditions myocarditis and pericarditis while they had COVID-19. Research published in JAMA Neurology in July 2020 identified 31 strokes among 1,683 COVID-19 patients admitted to the emergency room at two New York City hospitals, a 7.6-fold greater risk than for those who were admitted for flu. This estimate has fallen a bit as more data have accrued, but the trend is holding that SARS-CoV-2 presents a greater risk of stroke than other viruses, especially among older patients with preexisting health complications, study author and Weill Cornell Medical College neurologist Alexander Merkler tells The Scientist. Similarly, research published in The Lancet in July found that COVID-19 patients are three times more likely to have a heart attack in the week after their diagnosis than healthy controls. Many of these cardiovascular outcomes have the potential to become chronic health issues, especially among older patients or those with medical conditions such as diabetes and hypertension, according to a literature review published in Circulation Research.
Its not uncommon to see these cardiovascular manifestations take effect in patients with underlying heart disease or patients with severe COVID, Aeshita Dwivedi, an assistant professor of cardiology at Lenox Hill Hospital in New York tells The Scientist.
Throughout the pandemic, scientists have been probing health records, examining patient tissue, and analyzing viral genomes in order to understand how SARS-CoV-2 affects the cardiovascular system. In addition to the high levels of inflammation associated with COVID-19, the disease can also cause hearts to enlarge as a result of how much harder they have to work during the infection, which can in turn lead to heart failure, notes Northwestern University cardiology professor Robert Bonow, who is also the editor-in-chief of JAMA Cardiology. And several studies involving autopsies and biopsies of the heart muscle and stem cell models found evidence of heart cells infected with SARS-CoV-2, indicating that the coronavirus seems to be able to injure the heart directly as well as indirectly. Meanwhile, scientists are still grappling with the possible implications of long COVID, which remains enigmatic because reliable data sets are only now starting to emerge. Also unknown is whether Omicron, now the dominant variant in the United States, will affect the heart any differently than prior variantsthe best data available are still too preliminary to draw conclusions.
Manish Bansal, a cardiologist at the Medanta hospital in India, points out that overall rates of cardiovascular events related to COVID-19 are low. So, these figures should not lead to fear, he writes in an email, but yes, at [the] population level, they are worrisome because COVID-19 has affected millions of people and therefore the absolute burden of cardiovascular events is going to be large.
SARS-CoV-2 may be unique in the level of risk it poses to the heart, but like other viruses, many of the cardiovascular risks associated with COVID-19 stem from severe inflammation, researchers tell The Scientist. UVA Health emergency cardiologist William Brady says the increase in cardiovascular health problems that doctors report encountering likely stems from the fact that COVID-19 causes particularly severe inflammation compared to other viruses. Even in the absence of a direct assault on the heart, severe inflammation is bad news for the cardiovascular system due to the added strain it imposes on the heart and the bodys vasculature.
Indeed, viral inflammation like that caused by the coronavirus seems to increase ones risk of dying from any cause by accelerating the aging process, Brigham and Womens Hospital physician and infectious disease specialist John Ross tells The Scientist over email. He cites a 2015 study in PLOS ONE that scoured the health records of 160,481 patients to link biomarkers of an inflammatory responseincluding C-reactive protein, albumin, and neutrophilsto a heightened risk of all-cause mortality. In the case of SARS-CoV-2, the inflammation occurs all around the body, not just in the lungs as seen with the respiratory inflammation caused by the flu. That inflammation doesnt spare any part of your body, Dwivedi says.
In addition to injuring the body directly, this inflammatory response can also trigger programmed cell death: infection activates the apoptosis-directing gene caspase-8, according to an analysis of postmortem lung samples published last October.
Early on in the pandemic, SARS-CoV-2 became notorious for its ability to cause cytokine storms, severe immunological responses to infection that attack a pathogen so ferociously that they damage the bodys organs. A literature review published last March in Frontiers in Immunologysuggests that the cytokine storms caused by SARS-CoV-2 are different from and more dangerous than those caused by influenzas and other coronaviruses. These storms are unusually bad in COVID-19, J. David Spence, a neurologist and stroke prevention expert at the Robarts Research Institute, tells The Scientist. Specifically, a Sciencestudy determined how SARS-CoV-2 infections cause dysregulation of the antimicrobial type-I interferons secreted by immune cells to fight pathogens. That leads to not only a greater number but also a greater variety of cytokines being released into the system, which results in greater immunological havoc than with other infections.
The inflammation caused by COVID-19 may be more severe than that caused by other viruses, but inflammation alone cant explain all of COVID-19s cardiovascular effects. COVID-19 causes symptoms that are different from and more diverse than those of other respiratory diseases, which is why its much more complicated than the average pneumonia or influenza, says Bonow.
He explains that COVID-19 cytokine storms cause a hyper coagulable state that increases the risk of blood clots, stroke, and heart attacks. In this storm-induced coagulable state, Spence says that platelets aggregate together, creating plugs that can get stuck in the heart or elsewhere in the circulatory system and restrict or block blood flow, although the mechanism behind the formation of these plugs hasnt been determined yet. Bonow suggests that cytokine storms contribute in some way to this coagulable state and what he calls intense blood clotting during COVID-19.
Theres also accumulating evidence that the coronavirus can infect human cardiomyocytes, the hearts muscle cells. However, several of the studies probing this direct infection phenomenon were inconclusive, experts say. Its difficult to draw conclusions from stem cell models because the human body behaves very differently from cells in a dish, Cincinnati Childrens Hospital molecular cardiovascular biologist Kelly Grimes tells The Scientist in an email, and squirting a ton of virus on some cardiomyocytes isnt a good model for how those cells might encounter the virus in the body.
As of yet, its unclear whether viral infection of heart cells is causing any of COVID-19s symptoms or factoring into disease severity, Grimes adds. Determining if the cells get directly infected by the virus will allow us to understand if the dysfunction were finding in them is a primary or secondary effect of the virus.
So, is there a direct injury effect of the virus on the myocardium? says Brady. I think the thought is yes there is, but . . . we need to understand more about the direct effect of the virus on the myocardium. Thats not conclusively sorted out.
However the damage is inflicted, if the heart muscle, or myocardium, suffers injury, it could lead to a large number of people with weak hearts over time, potentially leading to chronic health conditions or an uptick in heart attacks in the future, Bonow says.
Multiple researchers tell The Scientist that they expect to see the bulk of these problems among patients who had underlying health issues before catching COVID-19. But Brady notes that theres not a scientific consensus regarding whether COVID-19 causes new cardiovascular issues that wouldnt have happened on their own or if its inducing these health problems among those who had preexisting risk factors.
More generally, as they look toward the future of the pandemic and beyond, researchers are now trying to chase down the diseases long-term implications, Bonow says. I think theres still a lack of understanding of what long COVID is all about, he says. Everybodys in the knowledge-gathering stage regarding longer-term effects at this point.
However, the general consensus within the scientific literature is that COVID-19 cases are associated with an uptick in cardiovascular health problems in the long run. An April 2021 paper from the American College of Cardiology highlights patient reports of cardiopulmonary symptoms such as fatigue long after their coronavirus infections waned, and an October review in Nature Reviews Cardiologysuggests that long COVID can cause an increased risk of heart palpitations and arrhythmias.
Maybe it shouldnt be that surprising that COVID, which causes a very severe and very prolonged inflammatory state, is associated with a high risk of heart problems over a long period of time, Ross says. However, Bonow notes, determining whether a cardiovascular complication was caused by an acute injury that happened to manifest later on or if its actually tied to long COVID is difficult. Part of the difficulty, says Dwivedi, is that long COVID is really a diagnosis of exclusion, meaning that clinicians need to rule out the myriad other explanations for a patients symptoms before attributing them to a past SARS-CoV-2 infection.
Several clinicians tell The Scientist that theyve witnessed an increase in cardiovascular health issues among the general population as the pandemic progressed. Indeed, research published in the American Heart Association journal Circulation in May of last year identified an atypical annual increase in deaths caused by heart disease and cerebrovascular diseases in 2020. These could stem from a drop in the number of doctor visits among people who wanted to avoid hospitals lest they get exposed to the coronavirus, experts say.
The confusion surrounding long COVID illustrates how much is left to learn about COVID-19 across the board. The first cases of the disease emerged at the end of 2019, and while it may not feel that way to those living through the pandemic, two years is an extremely short time when it comes to determining the long-term effects of a new disease.
For most other diseases, we have years and years of data, says Dwivedi. This diseasebarely any time has passed by.
When it comes to prevention and mitigation of cardiovascular outcomes caused by COVID-19, all eyes are on the continued performance of the various vaccines approved for use.
As with the long-term effects of COVID-19, its too early in the pandemic to know whether vaccines will help stave off secondary health outcomes such as cardiovascular complications in people who get breakthrough infections. Figuring out whether thats the case is a top priority for many researchers and clinicians, experts tell The Scientist, but not nearly enough time has passed since the vaccine rollout began to offer a definitive answer. Still, many offered up the hypothesis that vaccination will, in fact, help prevent problems including strokes, heart attacks, and heart disease, pointing to the vaccines ability to lessen the severity of SARS-CoV-2 infections.
If I were to be a betting person, I would say the incidence of cardiovascular complications should be lower in patients after vaccination, says Aeshita Dwivedi, an assistant professor of cardiology at Lenox Hill Hospital in New York. The vaccine kind of blunts the severity of the disease, so it can be hypothesized that vaccination should reduce the cardiovascular burden of COVID. But its a little too soon to say.
Columbia University neurologist Mitchell Elkind, a former president of the American Heart Association, agrees. He tells The Scientistthat most complications are associated with the course of the disease. It stands to reason that vaccination will lessen the chance of any secondary cardiovascular complication of COVID.
Read the original:
- Registration is open for the ISSCR 2022 Annual Meeting 15-18 June - EurekAlert - January 13th, 2022
- Stem cell: UC's odd 'unmention' in its top 10 research tales - Capitol Weekly - January 13th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Size Is Expected To Generate Huge Revenue and Competitive Outlook Industrial IT - Industrial IT - January 13th, 2022
- Outsmarting Cancer: Next Generation Therapies - BioSpace - January 13th, 2022
- Legendary Bayer is Reinventing its Story with Cell and Gene Therapy - BioSpace - January 13th, 2022
- New Resource from NCCN Shares Evidence-Based Approaches to Recognize and Manage Graft-Versus-Host Disease after Stem Cell Transplantation - Newswise - January 11th, 2022
- Rising Focus on Exploring Potential of Stem Cells as Therapeutic Tools in Drug Targeting and Regenerative Medicine to Fuel Revenue Growth of Stem... - January 11th, 2022
- Stem Cell Media Market Statistics Based on Facts and Figures, 2022 to 2031 - Taiwan News - January 11th, 2022
- Regenerative Medicine: Innovation & Innovators leading online scientific event by IASRM in this pandemic - ThePrint - January 11th, 2022
- JPM22: Pfizer's big bet on mRNA, Biogen 'proven wrong' on Aduhelm price and the next cell therapies - BioPharma Dive - January 11th, 2022
- Severe Combined Immunodeficiency Treatment Market: Availability of Drugs and Immune-related Treatments Are Anticipated to Drive the Global Market -... - January 11th, 2022
- Peter Dirks, Asthma and Physics - Brain Tumour Research - January 9th, 2022
- Overview - Brain Tumor Stem Cell Research Lab - Mayo ... - January 7th, 2022
- Religious Groups Official Positions on Stem Cell Research ... - January 7th, 2022
- EBMT trial demonstrates improvements in immunosuppressive treatment of patients with Severe Aplastic Anemia - EurekAlert - January 7th, 2022
- CMML vs. CML: What's the Difference? - Healthline - January 7th, 2022
- Effects of Stem Cell Therapy on Diabetic Mellitus Erectile Dysfunction: A Systematic Review and Meta-analysis - Newswise - January 5th, 2022
- Researchers Awarded Grant to Study New Method of Islet Transplantation - Weill Cornell Medicine Newsroom - January 5th, 2022
- FDA Grants Regenerative Medicine Advanced Therapy (RMAT) Designation to AlloVir's Posoleucel for the Treatment of Adenovirus (AdV) Infections in... - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- Worldwide Translational Regenerative Medicine Industry to 2026 - Ongoing Research in Organ Transplantation With Regenerative Medicine Presents... - January 5th, 2022
- These 2021 Biotech Breakthroughs Will Shape the Future of Health and Medicine - Singularity Hub - January 5th, 2022
- LifeBank Chain Announces Upcoming Gene and Cell Collaboration Platform With Disrupt Blockchain Technologies - Yahoo Finance - January 2nd, 2022
- Dental mesenchymal stromal/stem cells in different microenvironments implications in regenerative therapy - Newswise - January 2nd, 2022
- Bristol Myers Squibb exec on the companys growth in Seattle and beating cancer with immune cells - GeekWire - January 2nd, 2022
- Postdoc Position in Bioinformatics in Stem Cell Neurobiology job with MASARYK UNIVERSITY | 276195 - Times Higher Education (THE) - December 25th, 2021
- USC Stem Cell - December 25th, 2021
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 25th, 2021
- Researchers uncover new details behind inflammation that promotes heart disease - EurekAlert - December 25th, 2021
- Epithelial Cell Culture Media Market to hit US$ 303040.33 thousand by 2028, at 11.4% CAGR: The Insight Partners - Digital Journal - December 25th, 2021
- Global Regenerative Medicine Market is Expected to Reach USD 57.08 Billion by 2027, Growing at a CAGR of 11.27% Over the Forecast Period. -... - December 23rd, 2021
- Communication between cells plays a major role in deciding their fate > News > USC Dornsife - USC Dornsife College of Letters, Arts and Sciences - December 23rd, 2021
- Emendo Biotherapeutics and Seattle Childrens Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 23rd, 2021
- The 10 Most Compelling Research Stories of 2021 PharmaLive - PharmaLive - December 23rd, 2021
- UTSW working to reprogram cells to strengthen immunity in geriatric patients - EurekAlert - December 23rd, 2021
- Cell Proliferation Kit Market Objectives of the Study Includes Research Methodology and Assumptions and Forecast by 2031 - Digital Journal - December 23rd, 2021
- Drexel Researchers Develop and Employ Cell-Based Approach to Studying Mechanisms of Gulf War Illness - Drexel News Blog - December 21st, 2021
- This Startup Is Makingand ProgrammingHuman Cells - WIRED - December 21st, 2021
- Amniotics joins Vinnova funded 'CAMP' to improve outcome of lung transplantations with PulmoStem - marketscreener.com - December 21st, 2021
- COVID-19: Are T cell vaccines the future? - Medical News Today - December 21st, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 21st, 2021
- SpaceX CRS-24 launching multiple life science investigations to the International Space Station - EurekAlert - December 21st, 2021
- Fast food: Israeli team stumbles upon speed boost for slow-growing cultured meat - The Times of Israel - December 21st, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 21st, 2021
- End of Year Wrap Up: Key Updates in Myeloma in 2021 and Possible Upcoming FDA Updates - Cancer Network - December 21st, 2021
- City of Hope presents leading-edge research on blood cancer therapies and its vaccine to reduce stem cell transplant complications at American Society... - December 17th, 2021
- IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing... - December 17th, 2021
- Century Therapeutics Announces Presentation of Data at the 63rd American Society of Hematology ... - The Bakersfield Californian - December 17th, 2021
- Outlook on the Cell Isolation Global Market to 2026 - by Technique, Cell Type, Product, Application, End-use and Region - ResearchAndMarkets.com -... - December 17th, 2021
- CAR T-cell Therapy Found Equivalent to Standard of Care as Second-line Treatment for Aggressive non-Hodgkin Lymphoma - PRNewswire - December 15th, 2021
- Novel CD19-Directed CAR T-Cell Therapy Shows Favorable Results in R/R DLBCL - Targeted Oncology - December 15th, 2021
- Global CRISPR Technology Market Research Report 2021: Focus on Design Tools, Plasmid and Vector, Cas9 and G-RNA, & Delivery System Products -... - December 15th, 2021
- Building an entrepreneurial ecosystem is about a lot more than education and science funding - American Enterprise Institute - December 15th, 2021
- Q&A: Dr. Thomas Rando on preventing age-related diseases and turning discoveries into cures - UCLA Newsroom - December 12th, 2021
- Neoleukin Therapeutics Announces Preclinical Data Highlighting Activity of NL-201 in Hematologic Malignancies at 63rd American Society of Hematology... - December 12th, 2021
- Ten Problems with Embryonic Stem Cell Research | The ... - December 11th, 2021
- New stem cell identified for lung tissue regeneration ... - December 11th, 2021
- Harvard Department of Stem Cell and Regenerative Biology ... - December 11th, 2021
- Stem Cells Australia | Australian research, stem cell ... - December 11th, 2021
- Research Assistant Stem Cell Project Job at The Florey Institute in Melbourne, Australia - The Conversation AU - December 11th, 2021
- Ethical issues cloud case report of unproven stem cell therapy for autism - Spectrum - December 11th, 2021
- Mesenchymal Stem Cells Market Size 2021 Emerging Technologies, Global Regions with Industry Share Analysis, Gross Margin, Regional Demand and Forecast... - December 11th, 2021
- For children, young adults with recurrent AML, immunotherapy shows promise Washington University School of Medicine in St. Louis - Washington... - December 11th, 2021
- UEA researchers reveal how immune cells use the bodys fat stores to fight infection - News-Medical.net - December 11th, 2021
- Sanford Health opens study of cell injections for arthritis - Sanford Health News - December 11th, 2021
- Cell types outside the pancreas make insulin, too, study shows - Yale News - December 11th, 2021
- Doctoral Student Finds Alternative Cell Option For Organs-On-Chips - Texas A&M University Today - December 11th, 2021
- Caring Cross Announces Publication in Nature Communications Demonstrating Effectiveness of Place-of-Care Manufacture of Anti-CD19 CAR T Cells for... - December 11th, 2021
- Stem cells and the future of health care - The Globe and Mail - December 9th, 2021
- How the body uses fat to fight infection - EurekAlert - December 9th, 2021
- The Ethics of Human Cloning and Stem Cell Research ... - December 7th, 2021
- An Overview of Stem Cell Research | The Center for ... - December 7th, 2021
- Global Research Antibodies Outlook to 2028: Rise in R&D Initiatives and an Increase in Neurobiology and Stem Cell Research are Key Factors in Market... - December 7th, 2021
- University of Michigan Stem Cell Research | Frequently ... - November 30th, 2021
- Postdoctoral Research Associate in Centre for Stem Cells and Regenerative Medicine job with KINGS COLLEGE LONDON | 273388 - Times Higher Education... - November 30th, 2021
- Stem cell therapy potentially could treat Type 1 diabetes by helping patients produce insulin - USA TODAY - November 30th, 2021
- UCLA Broad Stem Cell Research Center receives $5 million ... - November 30th, 2021
- ReproCELL Incorporated : Everything you need to know about the REPROCELL iPSC Biobank - marketscreener.com - November 30th, 2021